Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Syndax Pharmaceuticals, Inc. - Common Stock (NQ:SNDX)

10.57 +1.27 (+13.66%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Syndax Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Let's uncover which stocks are experiencing notable gaps during today's session.
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday. 
Via Chartmill
Agilysys, Amer Sports, X Financial And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr)
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Earnings Scheduled For May 5, 2025
Via Benzinga
Syndax Pharmaceuticals's Earnings: A Preview
Via Benzinga
Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Syndax Announces Participation in May Investor Conferences
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Syndax Reports First Quarter 2025 Financial Results and Provides Business Update
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
NXP Semiconductors, Brinker International, Ultra Clean, Sanmina And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Why Leggett & Platt Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Syndax's Revuforj Earns Strong Physician Support, JP Morgan Predicts Sales Growth
JP Morgan raised Syndax's price target to $41, citing strong early Revuforj sales and physician confidence in its use for acute leukemias and NPM1 AML. 
Via Benzinga
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Earnings Scheduled For March 3, 2025
Via Benzinga
Syndax Announces Participation in March Investor Conferences
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Here's How Donald Trump Could Shake Up Health Care — And Biotech Stocks
Biotech stocks have slumped 15% since Donald Trump won his second presidency. That's because Trump comes with unknowns. 
Via Investor's Business Daily
Topics Government
Exposures Political
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Roku To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer
Syndax Pharmaceuticals announces positive Phase 2 trial results for revumenib in relapsed/refractory mNPM1 AML, with key milestones expected in 2024 and 2025. 
Via Benzinga
This Sempra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication
The FDA has approved Incyte and Syndax Pharmaceuticals' Niktimvo for chronic graft-versus-host disease in patients after at least two prior therapies, providing new hope for those with this serious... 
Via Benzinga
Exposures Product Safety
Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)
From Incyte and Syndax Pharmaceuticals
Via Business Wire
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
From Sagimet Biosciences Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback